Navigation Links
Sysmex America Set to Launch New XT-Series(TM) Parameters
Date:10/30/2008

FDA-Cleared Parameters Aid in the Diagnosis of Infectious and Inflammatory

Diseases and in Monitoring Iron Deficiency

MUNDELEIN, Ill., Oct. 30 /PRNewswire/ -- Sysmex America, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared Sysmex's Immature Granulocyte (IG) parameter and Reticulocyte Hemoglobin Equivalent (RET-He) parameter for use on the company's XT-Series(TM) Automated Hematology Analyzers for low to mid-volume laboratories, said John Kershaw, President, Sysmex America, Inc. This announcement follows the company's earlier clearances of the same parameters for the Sysmex XE-Series(TM) Automated Hematology Analyzers. Now, clinical laboratories of any size can potentially benefit from enhanced diagnostic information, workflow process improvement, and greater cost-effectiveness, added Kershaw. The IG parameter is now available on both the XT-2000i and the XT-1800i, and the RET-He is available on the XT-2000i Automated Hematology Analyzers. Sysmex is the only company able to provide both of these FDA-cleared parameters.

"As a partner to clinical laboratories nationwide, Sysmex is committed to expanding the clinical utility of our hematology product line. These FDA clearances demonstrate our company's dedication to best-in-class hematology products and empowers clinical laboratories to improve their operations while enhancing patient care," said Kershaw.

About Immature Granulocytes and the Sysmex IG Parameter

The identification of immature granulocytes is primarily of importance in the diagnosis of infectious and inflammatory diseases. The IG parameter on the Sysmex XT-Series Automated Hematology Analyzers provides a quantitative immature granulocyte count for metamyelocytes, myelocytes and promyelocytes by utilizing Sysmex's patented fluorescent flow cytometry technology. This patented technology, used to separate white blood cells into distinct cell clusters, reduces labor-intensive manual WBC differential procedures, and improves turnaround time for results critical to patient care. Prior to Sysmex's automated immature granulocyte counting, manual differential counting of immature granulocytes was slow, expensive and imprecise.

About Reticulocytes and the Sysmex RET-He Parameter

The RET-He parameter is a sensitive measurement of iron available for red cell production. Functional iron available for incorporation into the red cell hemoglobin can be monitored via the RET-He, thus assisting physicians monitoring disease states where iron deficiency is often seen. Less than normal hemoglobin content in reticulocytes, immature red blood cells (RBCs), is an indication of inadequate iron supply relative to demand. The amount of hemoglobin in these reticulocytes also corresponds to the amount of hemoglobin in mature RBCs. The RET-He parameter provides a direct measurement of the mean reticulocyte hemoglobin content. Therefore, it is a useful parameter for assisting physicians with early diagnosis of iron deficiency (iron restricted erythropoiesis), and for optimizing iron therapy.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems. Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide. For more information about Sysmex, please visit http://www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sysmex Announces Clinical Laboratory Software Name Change
2. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
3. One of Nations Oldest Blood Services Providers Turns to Sysmex America
4. American Oriental Bioengineering, Inc. to Report Third Quarter 2008 Financial Results
5. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
6. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
7. CPC of America Announces Agreement with BC Tech for Manufacture of MedClose(TM) Vascular Closure System
8. Stenum Hospital Does its 600th American Disc Replacement Surgery
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
11. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):